US2013196990A1PendingUtilityA1

Benzimidazole Derivatives As PI3 Kinase Inhibitors

58
Assignee: QU JUNYAPriority: Oct 6, 2010Filed: Sep 23, 2011Published: Aug 1, 2013
Est. expiryOct 6, 2030(~4.2 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 37/00A61P 35/02A61P 29/00A61K 31/5377C07D 235/24C07D 409/10C07D 235/08C07D 235/10C07D 413/04C07D 403/04C07D 417/04C07D 405/04C07D 401/10C07D 417/10C07D 405/10A61K 31/337C07D 403/10C07D 413/10
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 .- 16 . (canceled) 
     
     
         17 . A process for the preparation of the compound of formula (5) 
       
         
           
           
               
               
           
         
         comprising the cyclization with hydrazine of the compound of formula (4) 
       
       
         
           
           
               
               
           
         
         wherein 
         R2 is selected from H, —NHRa, alkoxy, halogen, —C 3 , —CHF 2 , and C 1-6 alkyl; 
         R3 is selected from aryl and heteroaryl, wherein said aryl or heteroaryl may be substituted by one to three Rc; 
         R4 is selected from H or Ra; 
         each R5 is independently selected from C 1-6 alkyl; 
         each Ra is independently selected from C 1-3 alkyl; 
         each Rc is independently selected from C 1-3 alkyl, halogen, —CF 3 , and hydroxy; and 
         n is 0-2.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.